Crohn's Disease Increases the Mesothelial Properties of Adipocyte Progenitors in the Creeping Fat.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
20 Apr 2021
Historique:
received: 10 03 2021
revised: 13 04 2021
accepted: 16 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 26 5 2021
Statut: epublish

Résumé

Our understanding of the interplay between human adipose tissue and the immune system is limited. The mesothelium, an immunologically active structure, emerged as a source of visceral adipose tissue. After investigating the mesothelial properties of human visceral and subcutaneous adipose tissue and their progenitors, we explored whether the dysfunctional obese and Crohn's disease environments influence the mesothelial/mesenchymal properties of their adipocyte precursors, as well as their ability to mount an immune response. Using a tandem transcriptomic/proteomic approach, we evaluated the mesothelial and mesenchymal expression profiles in adipose tissue, both in subjects covering a wide range of body-mass indexes and in Crohn's disease patients. We also isolated adipose tissue precursors (adipose-derived stem cells, ASCs) to assess their mesothelial/mesenchymal properties, as well as their antigen-presenting features. Human visceral tissue presented a mesothelial phenotype not detected in the subcutaneous fat. Only ASCs from mesenteric adipose tissue, named creeping fat, had a significantly higher expression of the hallmark mesothelial genes mesothelin (

Identifiants

pubmed: 33924264
pii: ijms22084292
doi: 10.3390/ijms22084292
pmc: PMC8074767
pii:
doi:

Substances chimiques

Biomarkers 0
MSLN protein, human 0
Mesothelin J27WDC343N

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministerio de Economía y Competitividad
ID : RTI2018-093919
Organisme : Instituto de Salud Carlos III
ID : PI17/01503
Organisme : Instituto de Salud Carlos III
ID : PI18/00037

Références

Clin Exp Immunol. 1995 Jul;101(1):172-6
pubmed: 7621585
J Exp Biol. 2018 Mar 7;221(Pt Suppl 1):
pubmed: 29514879
Am J Physiol Endocrinol Metab. 2005 Jan;288(1):E267-77
pubmed: 15383371
Gut. 2007 Apr;56(4):577-83
pubmed: 16956921
Cell Metab. 2018 Aug 7;28(2):300-309.e4
pubmed: 29937373
Physiol Rev. 2013 Jan;93(1):359-404
pubmed: 23303913
Development. 2018 Jan 4;145(1):
pubmed: 29158445
Cytotherapy. 2003;5(5):362-9
pubmed: 14578098
Stem Cells. 2016 Oct;34(10):2559-2573
pubmed: 27352919
Adipocyte. 2015 Jan 29;4(3):217-21
pubmed: 26257994
Stem Cells. 2007 Jul;25(7):1753-60
pubmed: 17395776
Cell Metab. 2013 Mar 5;17(3):411-22
pubmed: 23473035
Elife. 2018 Sep 28;7:
pubmed: 30265241
BBA Clin. 2015 Nov 05;5:16-24
pubmed: 27051585
Kidney Int. 2000 Feb;57(2):476-86
pubmed: 10652024
Stem Cells Transl Med. 2016 Apr;5(4):464-75
pubmed: 26956208
Blood. 2009 Sep 24;114(13):2632-8
pubmed: 19654411
Diabetes. 2013 Aug;62(8):2762-72
pubmed: 23493569
Organogenesis. 2013 Jan-Mar;9(1):3-10
pubmed: 23538753
Antioxid Redox Signal. 2015 Sep 1;23(7):597-612
pubmed: 25714483
APMIS. 2011 Nov;119(11):782-93
pubmed: 21995632
Blood. 2006 Jun 15;107(12):4817-24
pubmed: 16493000
Nat Metab. 2020 Jan;2(1):97-109
pubmed: 32066997
Genes Dev. 2017 Jan 15;31(2):127-140
pubmed: 28202540
Front Physiol. 2018 Jun 15;9:738
pubmed: 29962968
Clin Epigenetics. 2017 May 3;9:48
pubmed: 28473875
Lancet Gastroenterol Hepatol. 2016 Nov;1(3):238-247
pubmed: 28404096
Sci Rep. 2016 Sep 09;6:32925
pubmed: 27611009
Development. 2018 Aug 17;145(17):
pubmed: 30045918
Tissue Cell. 2017 Feb;49(1):95-105
pubmed: 27890350
Cytotherapy. 2013 Jun;15(6):641-8
pubmed: 23570660
Science. 2019 Apr 26;364(6438):
pubmed: 31023895
J Crohns Colitis. 2021 Jan 07;:
pubmed: 33411893
Nat Rev Mol Cell Biol. 2019 Apr;20(4):242-258
pubmed: 30610207
Int J Obes (Lond). 2016 Jan;40(1):112-20
pubmed: 26248660
Cell Metab. 2014 Jan 7;19(1):8-20
pubmed: 24239569
Nature. 2018 Jul;559(7712):103-108
pubmed: 29925944
Dev Dyn. 2016 Mar;245(3):307-22
pubmed: 26638186
Cytotherapy. 2016 Feb;18(2):151-9
pubmed: 26724220
Stem Cells. 2006 May;24(5):1246-53
pubmed: 16410391
Cytometry A. 2010 Jan;77(1):22-30
pubmed: 19852056
Cell Rep. 2014 Nov 6;9(3):1007-22
pubmed: 25437556
Trends Endocrinol Metab. 2015 Oct;26(10):515-523
pubmed: 26412153
Inflamm Bowel Dis. 2015 Nov;21(11):2590-7
pubmed: 26222339
Can J Gastroenterol. 2005 Sep;19 Suppl A:5A-36A
pubmed: 16151544
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Stem Cell Reports. 2014 Feb 06;2(2):171-9
pubmed: 24527391
J Cell Mol Med. 2011 Oct;15(10):2095-105
pubmed: 21070599
Immunity. 2017 Dec 19;47(6):1154-1168.e6
pubmed: 29221731
Stem Cells. 2007 Feb;25(2):271-8
pubmed: 16990583
Kidney Int. 1990 Jun;37(6):1563-70
pubmed: 2362409
Cell Rep. 2019 Apr 30;27(5):1528-1540.e7
pubmed: 31042478
Stem Cell Reports. 2017 Oct 10;9(4):1109-1123
pubmed: 28966116
Cell Metab. 2017 Mar 7;25(3):673-685
pubmed: 28215843
PLoS One. 2013;8(2):e55181
pubmed: 23405120
J Crohns Colitis. 2019 Jan 1;13(1):79-91
pubmed: 30272118
Nat Cell Biol. 2014 Apr;16(4):367-75
pubmed: 24609269
Int J Gynecol Cancer. 2016 Jun;26(5):833-8
pubmed: 27120688
Blood. 2006 Mar 15;107(6):2570-7
pubmed: 16293599
PLoS One. 2013;8(3):e57892
pubmed: 23526958
Cell. 2020 Oct 29;183(3):666-683.e17
pubmed: 32991841
Front Bioeng Biotechnol. 2015 Aug 17;3:117
pubmed: 26347862
Cell Stem Cell. 2018 Aug 02;23(2):166-179
pubmed: 29754780
Annu Rev Immunol. 1999;17:221-53
pubmed: 10358758
Cell Death Dis. 2014 Jun 26;5:e1304
pubmed: 24967966
J Dig Dis. 2018 Aug;19(8):475-484
pubmed: 30062772
Immunol Rev. 2009 May;229(1):294-306
pubmed: 19426229
J Biol Chem. 2003 Mar 14;278(11):9850-5
pubmed: 12519759
Stem Cells Transl Med. 2014 Feb;3(2):206-17
pubmed: 24361924
Surg Obes Relat Dis. 2011 Jan-Feb;7(1):60-7
pubmed: 20678967

Auteurs

Ana Madeira (A)

Department of Research, Institut d'Investigació Sanitària Pere Virgili, Hospital Universitari de Tarragona Joan XXIII, 43005 Tarragona, Spain.
Instituto de Salud Carlos III, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 08029 Madrid, Spain.

Carolina Serena (C)

Department of Research, Institut d'Investigació Sanitària Pere Virgili, Hospital Universitari de Tarragona Joan XXIII, 43005 Tarragona, Spain.
Instituto de Salud Carlos III, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 08029 Madrid, Spain.

Miriam Ejarque (M)

Department of Research, Institut d'Investigació Sanitària Pere Virgili, Hospital Universitari de Tarragona Joan XXIII, 43005 Tarragona, Spain.
Instituto de Salud Carlos III, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 08029 Madrid, Spain.

Elsa Maymó-Masip (E)

Department of Research, Institut d'Investigació Sanitària Pere Virgili, Hospital Universitari de Tarragona Joan XXIII, 43005 Tarragona, Spain.
Instituto de Salud Carlos III, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 08029 Madrid, Spain.

Monica Millan (M)

Department of Research, Institut d'Investigació Sanitària Pere Virgili, Hospital Universitari de Tarragona Joan XXIII, 43005 Tarragona, Spain.
Instituto de Salud Carlos III, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 08029 Madrid, Spain.
Department of Surgery, Colorectal Surgery Unit, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain.

M Carmen Navarro-Ruiz (MC)

Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), University of Cordoba, Reina Sofia University Hospital, Edificio IMIBIC, Avda. Menéndez Pidal s/n, 14004 Cordoba, Spain.
Department of Cell Biology, Physiology and Immunology, University of Cordoba, 14004 Cordoba, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.

Rocío Guzmán-Ruiz (R)

Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), University of Cordoba, Reina Sofia University Hospital, Edificio IMIBIC, Avda. Menéndez Pidal s/n, 14004 Cordoba, Spain.
Department of Cell Biology, Physiology and Immunology, University of Cordoba, 14004 Cordoba, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.

María M Malagón (MM)

Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), University of Cordoba, Reina Sofia University Hospital, Edificio IMIBIC, Avda. Menéndez Pidal s/n, 14004 Cordoba, Spain.
Department of Cell Biology, Physiology and Immunology, University of Cordoba, 14004 Cordoba, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.

Eloy Espin (E)

Colorectal Surgery Unit, General Surgery Service, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.

Marc Martí (M)

Colorectal Surgery Unit, General Surgery Service, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.

Margarita Menacho (M)

Digestive Unit, Hospital Universitari Joan XXIII, 43007 Tarragona, Spain.

Ana Megía (A)

Department of Research, Institut d'Investigació Sanitària Pere Virgili, Hospital Universitari de Tarragona Joan XXIII, 43005 Tarragona, Spain.
Instituto de Salud Carlos III, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 08029 Madrid, Spain.

Joan Vendrell (J)

Department of Research, Institut d'Investigació Sanitària Pere Virgili, Hospital Universitari de Tarragona Joan XXIII, 43005 Tarragona, Spain.
Instituto de Salud Carlos III, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 08029 Madrid, Spain.
Department Medicine and Surgery, Medicine School, Universitat Rovira i Virgili, 43003 Tarragona, Spain.

Sonia Fernández-Veledo (S)

Department of Research, Institut d'Investigació Sanitària Pere Virgili, Hospital Universitari de Tarragona Joan XXIII, 43005 Tarragona, Spain.
Instituto de Salud Carlos III, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 08029 Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH